Animal StudyPubMed ID: 21884635·2011

BPC-157 Reverses Gut Barrier Dysfunction in Intestinal Transplantation

Kang NS, Park JM, Lee JS, et al.

American Journal of Transplantation, 2011 · n = 40

Key finding

BPC-157 decreased permeability marker (FITC-dextran) by 72%, restored tight junction proteins, and reduced infarct size by 58% (p<0.001).

Summary

BPC-157 treatment restored intestinal barrier function and reduced ischemia-reperfusion injury in rat intestinal transplantation model.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

BPC-157L2

A gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. Despite over 100 preclinical studies, human clinical data remains extremely limited.

More research on BPC-157

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

Sports Health · 2025 · Review

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Alternative Therapies in Health and Medicine · 2025 · Human Pilot

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

Pharmaceuticals · 2024 · Review

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

Frontiers in Pharmacology · 2021 · Review

Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway

Scientific Reports · 2020 · Animal Study